Potential Risk Factors for Nivolumab-induced Thyroid Dysfunction

Background: Thyroid dysfunction is occasionally reported after the administration of nivolumab. We report on the incidence of and risk factors for nivolumab-induced thyroid dysfunction in patients with non-small lung cancer. Patients and Methods: A total of 82 patients who received nivolumab between...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:In Vivo
Huvudupphovsmän: YAMAZAKI, HARUHIKO, IWASAKI, HIROYUKI, YAMASHITA, TOSHINARI, YOSHIDA, TATSUYA, SUGANUMA, NOBUYASU, YAMANAKA, TAKASHI, MASUDO, KATSUHIKO, NAKAYAMA, HIROTAKA, KOHAGURA, KAORI, RINO, YASUSHI, MASUDA, MUNETAKA
Materialtyp: Artigo
Språk:Inglês
Publicerad: International Institute of Anticancer Research 2017
Ämnen:
Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5756657/
https://ncbi.nlm.nih.gov/pubmed/29102951
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/invivo.11195
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk